Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Jaribio la Kliniki la Awamu ya III× | Adaptive Randomized Clinical Trial× | |
|---|---|---|
| Nyanja | Epidemiolojia | Epidemiolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 1962 (Kefauver-Harris Amendment formalised phased drug development) | Late 1990s–2000s (widespread adoption post-2010) |
| Mwanzilishi≠ | FDA regulatory framework / ICH guidelines | Donald Berry and colleagues; formalized by FDA guidance in 2010 and 2019 |
| Aina≠ | Confirmatory randomised controlled trial | Experimental clinical trial design |
| Chanzo asilia≠ | Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185385 | Berry, D. A. (2006). Bayesian clinical trials. Nature Reviews Drug Discovery, 5(1), 27–36. DOI ↗ |
| Majina mbadala | Phase 3 trial, confirmatory trial, pivotal trial, Phase III RCT | adaptive RCT, adaptive trial design, response-adaptive randomization trial, adaptive clinical trial |
| Zinazohusiana | 6 | 6 |
| Muhtasari≠ | A Phase III clinical trial is a large-scale, confirmatory randomised controlled trial designed to establish the efficacy and safety of an intervention in the target patient population before regulatory submission. It builds on the signal identified in Phase II, tests the intervention at its proposed dose under controlled conditions, and provides the primary evidence base for marketing authorisation or guideline adoption. | An adaptive randomized clinical trial (adaptive RCT) is a prospective experimental study that uses pre-specified rules to modify one or more trial aspects — such as sample size, allocation ratios, or treatment arms — based on accumulating data collected during the trial itself, while maintaining statistical validity and integrity of the study. |
| ScholarGateSeti ya data ↗ |
|
|